Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Guanabenz acetate is a new centrally acting alpha 2-adrenergic agonist. Seventeen hypertensive men, in whom BP was normalized with guanabenz, underwent assessment of renal function, renal hemodynamics, and body fluid composition following short-term (three to six weeks), long-term (five to six months), and withdrawal (two weeks) therapy. Guanabenz therapy caused a modest but reversible reduction in glomerular filtration rate (12% to 18%), effective renal plasma flow (9% to 17%), and renal blood flow (12% to 20%). Renal vascular resistance was unchanged. Guanabenz therapy had no significant natriuretic or antinatriuretic effects in patients with an effective BP decrease, although it had the ability to produce and sustain a water diuresis. Guanabenz therapy was not associated with salt and water increases within body fluid compartments. Guanabenz, in some patients, is an effective monotherapy for the treatment of hypertension.
 ...
PMID:Effects of guanabenz therapy on renal function and body fluid composition. 686 45